Cargando…
Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274
BACKGROUND: c-Met is a receptor tyrosine kinase (RTK) that is over-expressed in a variety of cancers and involved in cell growth, invasion, metastasis and angiogenesis. In this study, we investigated the role of c-Met in rhabdomyosarcoma (RMS) using its small molecule inhibitor SU11274, which has be...
Autores principales: | Hou, Jinxuan, Dong, Jixin, Sun, Lijun, Geng, Liying, Wang, Jing, Zheng, Jialin, Li, Yan, Bridge, Julia, Hinrichs, Steven H, Ding, Shi-Jian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3212957/ https://www.ncbi.nlm.nih.gov/pubmed/21575221 http://dx.doi.org/10.1186/1479-5876-9-64 |
Ejemplares similares
-
Tyrosine kinase inhibitor SU11274 increased tumorigenicity and enriched for melanoma-initiating cells by bioenergetic modulation
por: Kucerova, Lucia, et al.
Publicado: (2016) -
Synergistic Effect of Afatinib with Su11274 in Non-Small Cell Lung Cancer Cells Resistant to Gefitinib or Erlotinib
por: Chen, Gang, et al.
Publicado: (2013) -
MET Inhibition Sensitizes Rhabdomyosarcoma Cells to NOTCH Signaling Suppression
por: Perrone, Clara, et al.
Publicado: (2022) -
Human Rhabdomyosarcoma Cell Lines for Rhabdomyosarcoma Research: Utility and Pitfalls
por: Hinson, Ashley R. P., et al.
Publicado: (2013) -
SPRY2 is a novel MET interactor that regulates metastatic potential and differentiation in rhabdomyosarcoma
por: Saini, Masum, et al.
Publicado: (2018)